Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedJun 10, 2026
DataAggregated Company Financials
Companies7
  • 7D-0.8%
  • 3M4.6%
  • 1Y-11.1%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.0%, driven by declines from every company within the industry. Overall the industry is down 11% in 12 months. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Jun 2026CHF 47.5bCHF 10.1bCHF 1.1b36.3x43.6x4.7x
Fri, 08 May 2026CHF 48.3bCHF 10.1bCHF 1.1b39.4x44.3x4.8x
Sun, 05 Apr 2026CHF 47.9bCHF 10.1bCHF 1.1b33.6x41.9x4.7x
Tue, 03 Mar 2026CHF 49.7bCHF 10.1bCHF 1.3b30.3x38.6x4.9x
Thu, 29 Jan 2026CHF 52.3bCHF 10.6bCHF 1.1b34.2x47.6x4.9x
Sat, 27 Dec 2025CHF 48.9bCHF 10.6bCHF 1.1b29.7x44.5x4.6x
Mon, 24 Nov 2025CHF 48.0bCHF 10.6bCHF 1.1b27.4x43.7x4.5x
Wed, 22 Oct 2025CHF 50.3bCHF 10.6bCHF 1.1b30.3x45.8x4.7x
Fri, 19 Sep 2025CHF 51.1bCHF 10.6bCHF 1.1b34.1x46.3x4.8x
Sun, 17 Aug 2025CHF 52.8bCHF 10.7bCHF 1.1b36x46.7x4.9x
Tue, 15 Jul 2025CHF 52.5bCHF 10.1bCHF 1.0b32.8x50.5x5.2x
Thu, 12 Jun 2025CHF 53.9bCHF 10.1bCHF 1.0b33.5x51.9x5.3x
Sat, 10 May 2025CHF 53.8bCHF 10.1bCHF 1.0b31.1x51.8x5.3x
Mon, 07 Apr 2025CHF 47.3bCHF 10.1bCHF 1.0b28.5x46.1x4.7x
Wed, 05 Mar 2025CHF 54.4bCHF 10.1bCHF 1.0b30.3x52.1x5.4x
Fri, 31 Jan 2025CHF 56.5bCHF 10.1bCHF 1.0b36.5x56.1x5.6x
Sun, 29 Dec 2024CHF 52.9bCHF 10.2bCHF 943.4m35.6x56.1x5.2x
Tue, 26 Nov 2024CHF 53.5bCHF 10.2bCHF 943.7m41.4x56.7x5.2x
Thu, 24 Oct 2024CHF 55.1bCHF 10.2bCHF 943.6m42x58.4x5.4x
Sat, 21 Sep 2024CHF 55.1bCHF 10.2bCHF 936.8m42.7x58.9x5.4x
Mon, 19 Aug 2024CHF 56.8bCHF 10.2bCHF 914.5m45.9x62.1x5.6x
Wed, 17 Jul 2024CHF 55.0bCHF 10.3bCHF 1.0b47.5x54.9x5.4x
Fri, 14 Jun 2024CHF 52.3bCHF 10.3bCHF 1.0b44.1x52.1x5.1x
Sun, 12 May 2024CHF 55.2bCHF 10.3bCHF 1.0b44.3x55.1x5.4x
Tue, 09 Apr 2024CHF 58.0bCHF 10.3bCHF 1.0b45.7x57.8x5.6x
Thu, 07 Mar 2024CHF 50.0bCHF 10.2bCHF 982.0m46.6x51x4.9x
Sat, 03 Feb 2024CHF 46.5bCHF 10.2bCHF 1.0b41.3x45.7x4.6x
Mon, 01 Jan 2024CHF 41.9bCHF 9.8bCHF 1.5b32.5x28x4.3x
Wed, 29 Nov 2023CHF 39.7bCHF 9.8bCHF 1.5b29.3x26.6x4.1x
Fri, 27 Oct 2023CHF 36.6bCHF 9.8bCHF 1.5b25.6x24.5x3.7x
Sun, 24 Sep 2023CHF 46.5bCHF 9.8bCHF 1.5b32.2x31.2x4.8x
Tue, 22 Aug 2023CHF 51.5bCHF 9.7bCHF 1.5b35.7x34.6x5.3x
Thu, 20 Jul 2023CHF 57.1bCHF 9.7bCHF 1.6b35.7x35x5.9x
Sat, 17 Jun 2023CHF 59.2bCHF 9.7bCHF 1.6b38.2x36.3x6.1x
Price to Earnings Ratio

36.3x


Total Market Cap: CHF 59.2bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 46.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.2x which is lower than its 3-year average PE of 46.4x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market-0.058%
Healthcare3.00%
Life Sciences-0.85%
Clinical Research and Equipment-0.85%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SKAN SKAN GroupCHF 51.702.8%
+CHF 31.5m		-31.5%PE71.4x

Latest News

LONN
CHF 495.30
Lonza Group
7D
-0.2%
1Y
-14.1%
BANB
CHF 68.45
Bachem Holding
7D
-3.6%
1Y
23.3%
Narrative Update • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
SKAN
CHF 51.70
SKAN Group
7D
2.8%
1Y
-31.5%
Narrative Update • Jun 03

SKAN: Order Backlog And Dividend Payouts Will Support Future Returns

Analysts have reaffirmed their CHF 62.50 price target for SKAN Group, citing only very small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions rather than any major change in the outlook. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.
SFZN
CHF 77.70
Siegfried Holding
7D
-0.8%
1Y
-20.8%
Narrative Update • Jun 01

SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside

Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment.
TECN
CHF 154.00
Tecan Group
7D
-1.8%
1Y
-10.9%
Narrative Update • May 31

TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential

Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.
PPGN
CHF 35.30
PolyPeptide Group
7D
-7.8%
1Y
59.7%
XLS
CHF 22.70
Xlife Sciences
7D
-5.4%
1Y
14.9%